Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 5Endometrial Neoplasms 4Ovarian Neoplasms 2Locally Advanced Cervical Carcinoma 2Turcot syndrome 1Stomach Neoplasms 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1Recurrence 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Endometrioid 1Advanced Cervical Cancer 1

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2toripalimab 1sintilimab 1camrelizumab 1anlotinib 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cervical Cancer × sintilimab × Gynecologic × Clear all
NCT04590599 2023-12-18

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2 Completed
205 enrolled
Gynecologic

Advanced Cervical Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡